Safety and Efficacy of Subcutaneously Administered Efalizumab in Adults with Moderate-to-Severe Hand and Foot PsoriasisAn Open-Label Study

被引：0
|
作者：
Rajat Varma
Jennifer A. Cafardi
Wendy Cantrell
Craig Elmets
机构：
[1] University of Alabama Medical Center,UAB Department of Dermatology
来源：
American Journal of Clinical Dermatology | 2008年 / 9卷
关键词：
Psoriasis; Plaque Psoriasis; Dermatology Life Quality Index; Acitretin; Efalizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Introduction: Hand and foot psoriasis may be more disabling than psoriasis at other body locations because of its interference with daily functional activities. Most treatment options have limited efficacy, short duration of response, toxicity, intolerability, or inconvenience.
引用
收藏
页码：105 / 109
页数：4
相关论文
共 50 条
  • [1] Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis - An open-label study
    Varma, Rajat
    Cafardi, Jennifer A.
    Cantrell, Wendy
    Elmets, Craig
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2008, 9 (02) : 105 - 109
  • [2] Ain open-label study to evaluate the safety and efficacy of 1.0 mg/kg subcutaneously administered efatizumab in adults with moderate to severe hand or foot psoriasis
    Varma, Rajat
    Cafardi, Jennifer
    Cantrell, Wendy
    Elmets, Craig
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB183 - AB183
  • [3] Safety of Efalizumab Therapy in Patients with Moderate to Severe PsoriasisAn Open-Label Extension of a Phase IIIb Trial
    Tiffani Hamilton
    Alan Menter
    Ivor Caro
    Peter Compton
    Jeffrey Sobell
    Kim A. Papp
    Drug Safety, 2008, 31 : 715 - 726
  • [4] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan D.
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 60 - 61
  • [5] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Correia, Ana Pinto
    Natalie, Chitra R.
    Pierce, Evangeline
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB84 - AB84
  • [6] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    Isho, Nadine
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [7] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    Blauvelt, Andrew
    Bissonnette, Robert
    de Bruin-Weller, Marjolein
    Hide, Michihiro
    Sher, Lawrence
    Hussain, Iftikhar
    Chen, Zhen
    Khokhar, Faisal A.
    Beazley, Bethany
    Ruddy, Marcella
    Patel, Naimish
    Graham, Neil M. H.
    Ardeleanu, Marius
    Shumel, Brad
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (04) : 567 - 577
  • [8] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Diamant Thaçi
    Mette Deleuran
    Andrew Blauvelt
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Michihiro Hide
    Lawrence Sher
    Iftikhar Hussain
    Zhen Chen
    Faisal A. Khokhar
    Bethany Beazley
    Marcella Ruddy
    Naimish Patel
    Neil M. H. Graham
    Marius Ardeleanu
    Brad Shumel
    American Journal of Clinical Dermatology, 2020, 21 : 567 - 577
  • [9] SAFETY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Sierka, D.
    Coleman, A.
    Gherardi, G.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S92 - S92
  • [10] Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Mette Deleuran
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Ryszard Galus
    Takeshi Nakahara
    Seong Jun Seo
    Faisal A. Khokhar
    Jignesh Vakil
    Jing Xiao
    Ainara Rodriguez Marco
    Noah A. Levit
    John T. O’Malley
    Arsalan Shabbir
    American Journal of Clinical Dermatology, 2022, 23 : 393 - 408
12345